Abstract #1066

Reduced T2 Reveal Therapeutic Effect of the Antioxidant Vitamin E in the G93A-SOD1 Mouse Model of ALS

Selina Bucher^1,2, Heiko G. Niessen³, Thomas Kaulisch⁴, Michael Neumaier³, Albert C. Ludolph¹, Detlef Stiller³

¹Department of Neurology, University of Ulm, Ulm, Germany; ²Department of Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; ³In-Vivo Imaging Unit, Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; ⁴In-Vivo Imaging Unit, Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG,, Biberach, Germany

We investigated the effects of a preclinical antioxidant treatment with vitamin E on T2 relaxation time in order to evaluate if T2 is a sensitive non-invasive biomarker for the assessment of therapeutic approaches in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis (ALS). A clear benefit of Vitamin E treatment for a significantly reduced ALS progression was shown in the study by means of MRI and validated by histology. In more general terms, it was shown that the measurement of the relaxation time T2 enables for a longitudinal non-invasive evaluation of therapeutic approaches in the G93A-SOD1 mouse model of ALS.